Recent Updates
Recently added Catalysts

Lopressor

Phase 1

Healthy | Small molecule | Other |Viatris Inc.|Last Updated: Apr 23, 2024

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedACTIVE_CONTROLLEDBiomarker
Total Trials2
Total Enrollment39
FDA Designations
No designations recorded
Clinical Trials (2)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00648271Fed Study of Metoprolol Tartrate Tablets 25 mg and Lopressor® 50 mgPHASE1 COMPLETED 19Dec 1, 2002Jan 1, 2003Apr 23, 20241 United States
NCT00649116Fed Study of Metoprolol Tartrate Tablets 100 mg and Lopressor® 100 mgPHASE1 COMPLETED 20Dec 1, 2002Jan 1, 2003Apr 23, 20241 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Bioequivalence
within 30 days
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelCROSSOVER
PurposeOTHER
Treatment Arms
ArmTypeDescription
1EXPERIMENTALMetoprolol Tartrate Tablets 25 mg
2ACTIVE_COMPARATORLopressor® Tablets 50 mg
Interventions
NameTypeDescription
Metoprolol Tartrate Tablets 25 mgDRUG2x50mg, single dose fed
Lopressor® Tablets 50 mgDRUG1x50mg, single dose fed
Metoprolol Tartrate Tablets 100 mgDRUG100mg, single dose fed
Lopressor® Tablets 100 mgDRUG100mg, single dose fed
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: 1. Age: 18 years and older. 2. Sex: Male and non-pregnant, non-lactating female 1. Women of childbearing potential must have negative serum beta-human chorionic gonadotropin (HCG) pregnancy tests performed within 14 days prior to the start of the study and the evening prior ...

Countries:United States
Unlock Eligibility Criteria